预防和治疗 COVID-19 的药物再利用:临床前景。

Md Shahadat Hossain, Ithmam Hami, Md Sad Salabi Sawrav, Md Fazley Rabbi, Otun Saha, Newaz Mohammed Bahadur, Md Mizanur Rahaman
{"title":"预防和治疗 COVID-19 的药物再利用:临床前景。","authors":"Md Shahadat Hossain, Ithmam Hami, Md Sad Salabi Sawrav, Md Fazley Rabbi, Otun Saha, Newaz Mohammed Bahadur, Md Mizanur Rahaman","doi":"10.15190/d.2020.18","DOIUrl":null,"url":null,"abstract":"<p><p>SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and the lack of data regarding the long-term effects of such vaccines are a significant concern. In addition, although remdesivir was recently approved by the FDA to be used as a clinical drug against COVID-19, it hasn't stood out yet as a proven form of therapeutics. Such inability to produce a novel therapy has caused enough inconveniences for the affected people worldwide. Repurposing the already available drugs to fight against the virus seems to be a reasonable option amidst such uncertainty. Given the vast collection of potential treatment candidates to be explored against COVID-19, there is a decent chance that a success in this regard will serve the intermediary purpose of clinically treating the infection until a COVID-19 vaccine is widely distributed worldwide and will be able to treat COVID-19 patients that do not adequately respond to vaccines. Such treatments may prove very useful in future coronavirus outbreaks too. Proper research into these repurposing treatments may yield a certain insight into the field of novel treatment production as well. This review study accumulates a relevant set of information about drugs and vaccines against COVID-19, in terms of their repurposing properties and the specific phases of clinical trials they are undergoing across the world.  A potential timeline is also suggested to estimate when an effective result can be expected from the ongoing clinical trials for a better anticipation of the drug landscape. This study will hopefully help accelerate investment of resources into development and discovery of drugs and vaccines against the infection.</p>","PeriodicalId":72829,"journal":{"name":"Discoveries (Craiova, Romania)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758544/pdf/","citationCount":"0","resultStr":"{\"title\":\"Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.\",\"authors\":\"Md Shahadat Hossain, Ithmam Hami, Md Sad Salabi Sawrav, Md Fazley Rabbi, Otun Saha, Newaz Mohammed Bahadur, Md Mizanur Rahaman\",\"doi\":\"10.15190/d.2020.18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and the lack of data regarding the long-term effects of such vaccines are a significant concern. In addition, although remdesivir was recently approved by the FDA to be used as a clinical drug against COVID-19, it hasn't stood out yet as a proven form of therapeutics. Such inability to produce a novel therapy has caused enough inconveniences for the affected people worldwide. Repurposing the already available drugs to fight against the virus seems to be a reasonable option amidst such uncertainty. Given the vast collection of potential treatment candidates to be explored against COVID-19, there is a decent chance that a success in this regard will serve the intermediary purpose of clinically treating the infection until a COVID-19 vaccine is widely distributed worldwide and will be able to treat COVID-19 patients that do not adequately respond to vaccines. Such treatments may prove very useful in future coronavirus outbreaks too. Proper research into these repurposing treatments may yield a certain insight into the field of novel treatment production as well. This review study accumulates a relevant set of information about drugs and vaccines against COVID-19, in terms of their repurposing properties and the specific phases of clinical trials they are undergoing across the world.  A potential timeline is also suggested to estimate when an effective result can be expected from the ongoing clinical trials for a better anticipation of the drug landscape. This study will hopefully help accelerate investment of resources into development and discovery of drugs and vaccines against the infection.</p>\",\"PeriodicalId\":72829,\"journal\":{\"name\":\"Discoveries (Craiova, Romania)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758544/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discoveries (Craiova, Romania)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15190/d.2020.18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discoveries (Craiova, Romania)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15190/d.2020.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

SARS-CoV-2 是导致目前 COVID-19 大流行的新型冠状病毒株,它使全人类深受其害。大流行已经过去了几个月。然而,全世界仍在寻找有效的治疗方案来对抗病毒感染。第一种疫苗刚刚于 2020 年 12 月获得紧急批准,可在美国和英国使用。这些都是好消息,然而,此类疫苗在全球范围内的分布、病毒变异的可能性以及缺乏有关此类疫苗长期效果的数据,都是令人严重关切的问题。此外,尽管雷米替韦最近获得了美国食品及药物管理局的批准,可用作抗 COVID-19 的临床药物,但它尚未成为一种行之有效的治疗方法。这种无法生产新型疗法的情况给全世界的受感染者带来了诸多不便。在这种不确定的情况下,重新利用现有药物来抗击病毒似乎是一个合理的选择。鉴于COVID-19潜在候选治疗药物种类繁多,在COVID-19疫苗在全球广泛传播之前,这方面的成功很有可能起到临床治疗感染的中介作用,并能治疗对疫苗反应不佳的COVID-19患者。这种治疗方法在未来冠状病毒爆发时也可能非常有用。对这些再利用疗法的适当研究可能会对新型疗法的生产领域产生一定的启示。本综述研究积累了一系列关于针对 COVID-19 的药物和疫苗的相关信息,包括它们的再利用特性以及它们在世界各地正在进行的临床试验的具体阶段。 同时还提出了一个潜在的时间表,以估计正在进行的临床试验何时能取得有效结果,从而更好地预测药物前景。希望这项研究能有助于加快对抗病毒药物和疫苗的开发和发现的资源投入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.

SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and the lack of data regarding the long-term effects of such vaccines are a significant concern. In addition, although remdesivir was recently approved by the FDA to be used as a clinical drug against COVID-19, it hasn't stood out yet as a proven form of therapeutics. Such inability to produce a novel therapy has caused enough inconveniences for the affected people worldwide. Repurposing the already available drugs to fight against the virus seems to be a reasonable option amidst such uncertainty. Given the vast collection of potential treatment candidates to be explored against COVID-19, there is a decent chance that a success in this regard will serve the intermediary purpose of clinically treating the infection until a COVID-19 vaccine is widely distributed worldwide and will be able to treat COVID-19 patients that do not adequately respond to vaccines. Such treatments may prove very useful in future coronavirus outbreaks too. Proper research into these repurposing treatments may yield a certain insight into the field of novel treatment production as well. This review study accumulates a relevant set of information about drugs and vaccines against COVID-19, in terms of their repurposing properties and the specific phases of clinical trials they are undergoing across the world.  A potential timeline is also suggested to estimate when an effective result can be expected from the ongoing clinical trials for a better anticipation of the drug landscape. This study will hopefully help accelerate investment of resources into development and discovery of drugs and vaccines against the infection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Impact of Dementia on Patients with Hip Fracture. Discovery that cells have plasma membrane portals called porosomes that govern secretion. Impact of the reporting source on Platelet Inhibition and Treatment Outcomes (PLATO) trial deaths. High Sensitivity C-Reactive Protein as a Prognostic Indicator of Cardiovascular Disease in Severe Non-Diabetic COVID-19 Patients. Cardiac Involvement in Monkeypox Outbreak.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1